Abstract
Tumor-associated lymphocytes (TALs) isolated from malignant ascites (MA) represent a promising but under-explored therapeutic option for ovarian cancer (OC). This study investigated the efficacy and safety of TALs, either alone or in combination with chemotherapy, in 32 patients with MA. Patients were divided into three groups: TALs alone, chemotherapy alone, and combination therapy. The combination group demonstrated a significantly higher objective response rate (90.9%) compared to TALs (37.5%) and chemotherapy (53.8%) alone. Furthermore, combination therapy significantly extended median time to progression (13 months) and overall survival (25 months). Quality of life, measured by Karnofsky performance status and ascites-associated symptoms, also showed the most marked improvement in the combination arm. These results suggest that combining TAL-based immunotherapy with chemotherapy is a safe and superior strategy for managing malignant ascites in ovarian cancer patients.
Introduction
Ovarian cancer is a leading cause of cancer-related mortality in women, with a majority of patients eventually developing malignant ascites (MA). MA causes severe distress, including abdominal pain, distention, and nausea, and often becomes resistant to standard treatments. While adoptive cell transfer (ACT) using tumor-infiltrating lymphocytes (TILs) has shown success in other malignancies, the use of TALs—immune cells found directly within ascitic fluid—remains less studied. This research evaluates the clinical impact of re-infusing expanded TALs into patients, particularly when paired with chemotherapy, to improve both survival and quality of life.
Methodology
The clinical study involved 32 patients with MA arising from ovarian cancer.
- Treatment Groups: Patients received either TALs alone (n=8), chemotherapy alone (n=13), or a combination of TALs and chemotherapy (n=11).
- TAL Preparation: TALs were harvested from each patient's ascitic fluid and cultured in vitro with recombinant interleukin-2 (rIL-2) for 1–2 weeks. The goal was to reach a therapeutic dose of at least $10^9$ cells.
- Characterization: Flow cytometry was employed to identify the phenotypes of the expanded TALs, specifically $CD3^+$, $CD4^+$, and $CD8^+$ T cell populations.
- Administration: TALs were delivered via intraperitoneal (IP) injection. The chemotherapy regimen included intravenous liposome-paclitaxel and carboplatin.
- Evaluation Metrics: Outcomes were measured using the Karnofsky performance status (KPS), ascites-associated symptoms (AAS), time to progression (TTP), and overall survival (OS).
Results
TAL Characterization and Expansion
The expansion process was successful for all patients in the TAL groups. Morphologically, the cells transitioned from simple round shapes to complex, branching colonies as they reached an exuberant growth phase. Flow cytometric analysis confirmed the presence of the targeted T-cell populations, ensuring the therapeutic potential of the expanded cells.
Clinical Outcomes and Quality of Life
The combination therapy significantly outperformed both monotherapies:
- Ascites Control: The objective response rate for the combination group was 90.9%, nearly double that of the TAL-only group (37.5%).
- Survival: Median TTP was 13 months for the combination group, compared to 6 months for chemotherapy and only 1 month for TALs alone. Median OS was significantly longer in the combination group (25 months) than in the TAL-only group (7 months); while the trend favored combination over chemotherapy alone, the difference did not reach statistical significance in this small cohort.
- Patient Well-being: Patients in the combination group experienced the most significant improvements in KPS scores and a dramatic reduction in debilitating symptoms such as fatigue, insomnia, and abdominal pain.
Discussion
A key insight from this study is the synergistic "pre-conditioning" effect of chemotherapy. While chemotherapy is generally immunosuppressive, it can also deplete myeloid-derived suppressor cells (MDSCs) that inhibit immune responses. This reduction in the tumor's "shield" likely allows the infused TALs to target cancer cells more effectively. Furthermore, TALs offer a practical advantage over TILs as they are easily harvested from ascitic fluid without the need for invasive surgery.
Limitations and Future Directions
The study's primary limitation is the small sample size (N=32), which restricts the statistical significance of some survival comparisons. Additionally, future research should include a more detailed analysis of the immune microenvironment, specifically measuring MDSC and Regulatory T cell (Treg) levels, to better understand the mechanisms of synergy and further optimize treatment protocols.
Summary updated